Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, one of the biotechnology analysts at Goldman Sachs and we're pleased to have the Blueprint team with us. With us here on stage, we have Jeff Albers, CEO and President.
Questions & Answers
Jeff, maybe to start, earlier this year, you announced the 2020 Blueprint. Can you just update us on your progress towards the goals there and what we should expect for the rest of the year?
Sure. So first off, on behalf of all the Blueprint employees, thanks for including us at the conference. At a high level, I think the Blueprint 2020 embodies what we're trying to execute from a corporate vision perspective, and there's really 3 fundamental components of that one: the first is to leverage our kinase library, our chemical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
